Search Within

Advanced Practice Providers

  1. "2014"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (15)
  3. Book Section (1)
Groups
  1. Nursing (42)
  2. Department of Medicine (21)
  3. Center for Hematologic Malignancies (15)
  4. Survivorship Research (13)
  5. Hematologic Malignancies, Division of (12)
  6. Solid Tumor Oncology Division (11)

More Groups

People
  1. Jedd Wolchok (4)
  2. Kevin Curran (4)
  3. Margaret Callahan (4)
  4. Ruthann Gordon (4)
  5. Sergio Giralt (4)
  6. Alexander Lesokhin (3)

More People

Years
  1. 2014 (44)
Publications
  1. Biology of Blood and Marrow Transplantation (7)
  2. Journal of Clinical Oncology (6)
  3. Blood (3)
  4. Critical Care Medicine (3)
  5. BJU International (2)
  6. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (1)

More Publications

Publishers
  1. Elsevier Inc. (11)
  2. American Society of Clinical Oncology (6)
  3. Wiley Blackwell (5)
  4. Lippincott Williams & Wilkins (4)
  5. American Society of Hematology (3)
  6. Oxford University Press (2)

More Publishers

Results (44)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Micafungin versus posaconazole prophylaxis in adult patients with acute leukemia undergoing induction chemotherapy
    Meeting Abstract

    Huang, Y. T.; Aufiero, K.; Halton, E.; Quintanilla, H.; Baldwin, C.; Brutus, J.; Grome, N.; Nguyentran, T.; Senatus, G.; Turner, M.; more...
    Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC)
    Meeting Abstract

    O'Reilly, E. M.; Lowery, M. A.; Segal, M. F.; Smith, S. C.; Moore, M. J.; Kindler, H. L.; Golan, T.; Segal, A.; Salo-Mullen, E. E.; Hollywood, E.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results
    Meeting Abstract

    Lunning, M. A.; Ruan, J.; Nair, S.; Boruchov, A. M.; Byrne, R.; Gerecitano, J. F.; Hamlin, P. A.; Inserra, B.; Leonard, J.; Lynch, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Acute changes in endothelial function with cisplatin among germ cell tumor (GCT) patients (Pts)
    Meeting Abstract

    Feldman, D. R.; Jacobsen, E. P.; Woo, K.; Steingart, R.; Fleisher, M.; Patil, S.; Carousso, M.; Laguerre, S.; Morales, T. D.; Sheinfeld, J.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase 1b study of R05137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170)
    Meeting Abstract

    Abou-Alfa, G. K.; Yen, C. J.; Carrasquillo, J. A.; Hsu, C. H.; Gansukh, B.; Ma, J.; Hollywood, E.; Wan, P. J.; Shao, Y. Y.; Lin, Z. Z.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Myeloablative double-unit cord blood transplantation (CBT) in pediatric patients with high-risk acute leukemia demonstrates encouraging disease-free survival with both TBI and chemotherapy-only-based conditioning
    Meeting Abstract

    Scaradavou, A.; Lubin, M. N.; Hilden, P.; Boulad, F.; Curran, K. J.; Kobos, R.; Prockop, S. E.; O'Reilly, R. J.; Tonon, J. A.; Byam, C.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y. J.; Yoo, S.; Purdon, T.; Halton, E.; Quintanilla, H.; Curran, K. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save